MEXICO CITY, July 20, 2021 /PRNewswire/ — m8 Pharmaceuticals and Pharmanovia have signed an exclusive licensing agreement for a portfolio of several brands for Mexico & Brazil. This portfolio is comprised of well-known established brands for the treatment of cardiovascular, nervous system, and rheumatological illnesses. The main goal of the partnership is to continue to strengthen […]
Other News
Rivus Pharmaceuticals Launches with $35 Million Series A Financing to Develop Novel Treatments for Cardio-Metabolic Diseases
Advancing a pipeline of first-in-class Controlled Metabolic Accelerators (CMAs) to harness the body’s natural processes to improve cellular metabolism and treat the underlying causes of poor metabolic health and cardiovascular disease Initial programs to focus on type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection […]
Novocardia™ Announces Partnership with First Coast Heart & Vascular Cente
Alliance to Focus on Improving the Quality, Access, and Value of Cardiovascular Disease Care in Northeast Florida NEW YORK, July 20, 2021 /PRNewswire/ — Novocardia, a value-based cardiovascular disease care delivery platform, today announced a partnership with First Coast Heart & Vascular Center, P.C., the largest independent cardiovascular disease physician group in Northeast […]
CARMAT announces the first commercial implant of its Aeson® artificial heart
The implant, performed at the Azienda Ospedaliera dei Colli hospital in Naples, Italy, represents the first sale for CARMATand paves the way for the Company’s commercial development PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a […]
Ancora Heart Secures $80 Million in Financing
Beverly Huss to join Board of Directors SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced it has closed an $80 million equity financing. Sands Capital, Sio Capital and an undisclosed strategic investor joined all existing investors in this financing. The […]
Anthos Therapeutics’ novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine
Abelacimab achieved a ~80% reduction in venous thromboembolism versus a standard of care comparator in gold standard proof-of-concept efficacy study, indicating its potential in a range of thromboembolic disorders CAMBRIDGE, Mass., July 19, 2021 /PRNewswire/ — Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced final […]
Cytokinetics Announces Positive Topline Results of Redwood-HCM
Phase 2 Clinical Trial of CK-274 Demonstrated Consistent and Clinically Meaningful Reductions in Left Ventricular Outflow Tract Gradients Within Two Weeks in Patients with Obstructive Hypertrophic Cardiomyopathy No Treatment Interruptions or Discontinuations Due to Reduction in Left Ventricular Ejection Fraction Phase 3 Registrational Trial of CK-274 Expected to Start Before […]
Impulse Dynamics Expands Commercial Leadership Team
MARLTON, N.J., July 19, 2021 (GLOBE NEWSWIRE) — Impulse Dynamics (USA) Inc., a company dedicated to improving the lives of people with heart failure (HF), today announced the appointment of Jason Spees to the position of President, Chief Commercial Officer. Spees, who will be based in the company’s headquarters office […]
Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors
BOSTON, July 19, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Allison Dorval, chief financial officer of Voyager Therapeutics, Inc. (“Voyager”), as a member […]
Imbria Pharmaceuticals Announces Initiation of Enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the Safety, Tolerability, and Efficacy of IMB-1018972 (IMB-101) in Patients With Non-Obstructive Hypertrophic Cardiomyopathy
BOSTON–(BUSINESS WIRE)–Imbria Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapies designed to enhance cellular energetics for the treatment of major forms of heart disease and specific inborn errors of metabolism, today announced that the Hypertrophic Cardiomyopathy Center at Boston-based Tufts Medical Center has randomized the first patient in the […]
Recent
VahatiCor Enrolls First U.S. Patient in SERRA-I Clinical Study of A-FLUX Reducer System® for CMD
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
UBC MOSAIC and LifeLabs Unlock New Ways to Manage and Predict Heart Health
Popular
- No commented posts yet